数据与复现临床医学与医药FreedomIntelligence/OpenClaw-Medical-Skills数据与复现

myeloma-mrd-agent

维护者 FreedomIntelligence · 最近更新 2026年4月1日

Multiple myeloma MRD assessment from flow cytometry and NGS data.

OpenClawNanoClaw分析处理复现实验myeloma-mrd-agent🧠 bioos extended suitehematology & blood disordersmultiple

原始来源

FreedomIntelligence/OpenClaw-Medical-Skills

https://github.com/FreedomIntelligence/OpenClaw-Medical-Skills/tree/main/skills/myeloma-mrd-agent

技能摘要

2 min

Myeloma MRD Agent provides comprehensive AI-driven minimal residual disease assessment ，用于 multiple myeloma. It integrates next-generation flow cytometry (NGF)，NGS-based clonotype tracking，、 mass spectrometry M-protein detection ，用于 ultra-sensitive MRD monitoring。
When assessing MRD status in multiple myeloma patients post-treatment。
To select optimal MRD testing modality (NGF vs NGS vs MS)。
用于 predicting progression-free survival based on MRD kinetics。
When integrating MRD ，支持 other response criteria (IMWG)。

原始文档

NGF Analysis: AI-enhanced next-generation flow cytometry for MRD detection at 10^-5 to 10^-6 sensitivity.
NGS Clonotype Tracking: Analyze IGH/IGK/IGL rearrangements for molecular MRD.
Mass Spectrometry: MALDI-TOF or LC-MS/MS for M-protein detection.
Multi-Modal Integration: Combine modalities for comprehensive MRD assessment.
Kinetic Modeling: Track MRD dynamics and predict outcomes.
Response Classification: Apply IMWG MRD criteria.

Method	Sensitivity	Sample	Advantages
NGF (EuroFlow)	10^-5 to 10^-6	BM	Standardized, fast
NGS (clonoSEQ)	10^-6	BM	Ultra-sensitive
ASO-qPCR	10^-5	BM	Quantitative
PET-CT	N/A	Whole body	Extramedullary
MS (MALDI/LC-MS)	10^-5	Serum	Non-invasive

Category	Definition
MRD-negative (10^-5)	No clonal plasma cells by NGF or NGS at 10^-5
MRD-negative (10^-6)	No clonal plasma cells at 10^-6 sensitivity
Sustained MRD-neg	MRD-neg confirmed ≥1 year apart
Flow MRD-neg	NGF negative, sensitivity ≥10^-5
Sequencing MRD-neg	NGS negative, sensitivity ≥10^-5